FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The new Zigly center features and offers comprehensive veterinary services
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
The company’s largest center for medical device applications, serving the entire Asian market
Subscribe To Our Newsletter & Stay Updated
